A nucleus-targeting peptide antagonist towards EZH2 displays therapeutic efficacy for lung cancer

In Search of the Long-Desired ‘Copernican Therapeutic Revolution’ in Small-Cell Lung Cancer

(2020) Noemí Reguart et al.   DRUGS

Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer

(2020) Shira Yomtoubian et al.   Cell Reports

Tazemetostat: First Approval

(2020) Sheridan M. Hoy   DRUGS

Synthetic CXCR4 Antagonistic Peptide Assembling with Nanoscaled Micelles Combat Acute Myeloid Leukemia

(2020) Jie Meng et al.   Small

Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study

(2020) Mrinal Gounder et al.   LANCET ONCOLOGY

Enhanced lymphatic delivery of nanomicelles encapsulating CXCR4-recognizing peptide and doxorubicin for the treatment of breast cancer

(2020) Xiaocui Fang et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Recent Advances in Cell Penetrating Peptide-Based Anticancer Therapies

(2019) Justine Habault et al.   MOLECULES

Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy

(2019) Abdullah Al Emran et al.   TRENDS IN IMMUNOLOGY

Long-term delivery of protein and peptide therapeutics for cancer therapies

(2019) Sadia Sikder et al.   Expert Opinion on Drug Delivery

Current Diagnosis and Management of Small-Cell Lung Cancer

(2019) Shuhang Wang et al.   MAYO CLINIC PROCEEDINGS

Therapeutic Approaches Targeting Nucleolus in Cancer

(2019) Pietro Carotenuto et al.   Cells

Enhancer of zeste homolog 2 (EZH2) inhibitors

(2018) Nitya Gulati et al.   LEUKEMIA & LYMPHOMA

Unravelling the biology of SCLC: implications for therapy

(2017) Joshua K. Sabari et al.   Nature Reviews Clinical Oncology

Anti-tumor activity of nanomicelles encapsulating CXCR4 peptide antagonist E5

(2017) Xiaocui Fang et al.   PLoS One

Targeting EZH2 in cancer

(2016) Kimberly H Kim et al.   NATURE MEDICINE

A HSP60-targeting peptide for cell apoptosis imaging

(2016) S Yang et al.   Oncogenesis

Peptide therapeutics: current status and future directions

(2015) Keld Fosgerau et al.   DRUG DISCOVERY TODAY

Peptide-Based Treatment: A Promising Cancer Therapy

(2015) Yu-Feng Xiao et al.   Journal of Immunology Research

Peptide-Based Nanostructures for Cancer Diagnosis and Therapy

(2014) Linna An et al.   CURRENT MEDICINAL CHEMISTRY

EZH2 as a potential target in cancer therapy

(2014) Michael T McCabe et al.   Epigenomics

EZH2 Promotes E2F-Driven SCLC Tumorigenesis through Modulation of Apoptosis and Cell-Cycle Regulation

(2013) Roland Hubaux et al.   Journal of Thoracic Oncology

Delivery of drugs to cell membranes by encapsulation in PEG–PE micelles

(2012) Jing Wang et al.   JOURNAL OF CONTROLLED RELEASE

Histone methylation: a dynamic mark in health, disease and inheritance

(2012) Eric L. Greer et al.   NATURE REVIEWS GENETICS

Regulation of chromatin by histone modifications

(2011) Andrew J Bannister et al.   CELL RESEARCH

Ovarian Cancer Stem Cell-Like Side Populations Are Enriched Following Chemotherapy and Overexpress EZH2

(2011) S. Rizzo et al.   MOLECULAR CANCER THERAPEUTICS

The Polycomb complex PRC2 and its mark in life

(2011) Raphaël Margueron et al.   NATURE

Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo

(2010) Sha Hu et al.   CANCER BIOLOGY & THERAPY

Active targeting schemes for nanoparticle systems in cancer therapeutics

(2008) James D. Byrne et al.   ADVANCED DRUG DELIVERY REVIEWS

Nanoparticle therapeutics: an emerging treatment modality for cancer

(2008) Mark E. Davis et al.   NATURE REVIEWS DRUG DISCOVERY